---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Tislelizumab-jsgr - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/tislelizumab-jsgr
version: v1
---

# Tislelizumab-jsgr - NCI

# Tislelizumab-jsgr

Placeholder slot

(TIS-leh-LIZ-yoo-mab)

Tislelizumab-jsgr works by keeping cancer cells from suppressing the immune system. It binds to the protein PD-1 on the surface of immune cells called T cells, allowing the immune system to recognize and kill the cancer cells. Tislelizumab-jsgr is a type of immunotherapy (immune checkpoint inhibitor) and a type of targeted therapy (monoclonal antibody).

US Brand Name(s)

Tevimbra

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08ef1e3e-496f-4b0b-94ee-fbba3cc1985a&audience=consumer)

## Use in Cancer

Tislelizumab-jsgr
is approved to treat adults with:

- **[Esophageal cancer](/Common/PopUps/popDefinition.aspx?id=444989&version=Patient&language=English)** that cannot be removed by surgery or has spread to other parts of the body. It is used in patients with [squamous cell carcinoma](/Common/PopUps/popDefinition.aspx?id=46595&version=Patient&language=English) of the esophagus. It is given:
- with [platinum](/Common/PopUps/popDefinition.aspx?id=45841&version=Patient&language=English)-based chemotherapy as the first treatment in patients whose cancer has the [PD-L1](/Common/PopUps/popDefinition.aspx?id=797389&version=Patient&language=English) protein
- alone in patients whose cancer was treated with [systemic chemotherapy](/Common/PopUps/popDefinition.aspx?id=301626&version=Patient&language=English) that did not include a PD-L1 or [PD-1](/Common/PopUps/popDefinition.aspx?id=777027&version=Patient&language=English) inhibitor
- **[Gastric adenocarcinoma](/Common/PopUps/popDefinition.aspx?id=454513&version=Patient&language=English)**  or **[gastroesophageal junction](/Common/PopUps/popDefinition.aspx?id=302458&version=Patient&language=English) [adenocarcinoma](/Common/PopUps/popDefinition.aspx?id=46216&version=Patient&language=English)** that has the PD-L1 protein, is [HER2 negative](/Common/PopUps/popDefinition.aspx?id=774531&version=Patient&language=English), and cannot be removed by surgery or has spread to other parts of the body. It is given with platinum-based chemotherapy and a [fluoropyrimidine](/Common/PopUps/popDefinition.aspx?id=386207&version=Patient&language=English) as the first treatment.

Tislelizumab-jsgr
is also being studied in the treatment of other types of
cancer.

## More About Tislelizumab-jsgr

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/770893) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Tislelizumab-jsgr](https://medlineplus.gov/druginfo/meds/a624026.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Tislelizumab-jsgr](https://www.cancer.gov/research/participate/clinical-trials/intervention/C121775) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
